Cell type-associated traits map for the [FetalSkin_Smooth muscle cell][link to cell ontology]. Due to the large number of UKBB panel traits, this figure shows the non-UKBB traits with a CSEA p (chi2) < 1e-04 as default, and users can change it to 1e-03, 1e-05, or 1e-06. For each cell type and trait association pair (shown as an edge in the figure), there may be multiple TAG sets, each defined at a different threshold. The pair with the minimum p-value is shown in the figure, with the p-value showing along each edge. The number of edges in the figure is thus less than (or equal to) the number of entries in the table below.” The association association is listed in the table at bottom, Because each trait might have multiple TAG sets defined at different thresholds, multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns).
Table. List of Cell type-associated traits pairs for [FetalSkin_Smooth muscle cell]. If the network above is too complicated. the users could obtain the association information from the table at bottom. Because each trait has multiple TAG sets defined at different thresholds, there may be multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns). Users could identify the most significant association by sorting “CSAE p (chi2)” column.
| Trait Name | Trait Full Name | Panel | Author | Year | Cases* | Controls | TAG Set Threshold |
CSEA p (chi2) |
|---|---|---|---|---|---|---|---|---|
| Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 1.00e-2 | 8.23e-3 |
| Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 1.00e-3 | 5.53e-3 |
| Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 1.00e-4 | 1.17e-2 |
| Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 1.00e-5 | 2.58e-2 |
| Bone Mineral Density Estimated | Bone Mineral Density Estimated | MTC | Kemp | 2017 | NA | 142487 | 1.00e-2 | 4.06e-3 |
| Bone Mineral Density Estimated | Bone Mineral Density Estimated | MTC | Kemp | 2017 | NA | 142487 | 1.00e-3 | 3.76e-2 |
| Cerebral White Matter Hyperintensity | Cerebral White Matter Hyperintensity | MTC | Traylor | 2016 | NA | 3670 | 1.00e-3 | 3.87e-2 |
| CAD | Coronary Artery Disease | MTC | C4D | 2011 | 64762 | 22233 | 5.00e-2 | 3.28e-2 |
| CAD | Coronary Artery Disease | MTC | C4D | 2011 | 64762 | 22233 | 1.00e-2 | 4.00e-2 |
| Neuroticism | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 3.36e-2 |
| Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 5.00e-2 | 2.87e-2 |
| Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 1.00e-4 | 2.21e-2 |
| Partial Epilepsy | Partial Epilepsy | MTC | Kasperaviciute | 2010 | 3445 | 6935 | 1.00e-3 | 3.22e-2 |
| Tetralogy Of Fallot | Tetralogy Of Fallot | MTC | Cordell | 2013 | 835 | 5159 | 5.00e-2 | 1.24e-2 |
| Tiredness | Tiredness | MTC | Deary | 2018 | NA | 108976 | 1.00e-4 | 4.30e-2 |
| Albuminuria | Urinary Albumin to Creatinine Ratio | MTC | Teumer | 2016 | NA | 54450 | 1.00e-3 | 7.18e-3 |
| Albuminuria | Urinary Albumin to Creatinine Ratio In Diabetics | MTC | Teumer | 2016 | NA | 5825 | 5.00e-2 | 3.66e-2 |
| Alzheimers Protein Levels | Amyloid Beta 1 42 | MTC | Ramirez | 2014 | NA | 363 | 5.00e-2 | 1.35e-2 |
| Aortic Valve Calcification | Aortic Valve Calcification | MTC | Thanassoulis | 2013 | NA | 6942 | 1.00e-3 | 1.88e-2 |
| Blood Cells | Platelet Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 2.70e-2 |
| Blood Cells | Platelet Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 6.09e-4 |
| Blood Lipids | Triglycerides | ETC | Teslovich | 2010 | NA | 96598 | 1.00e-3 | 2.88e-2 |
| Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-2 | 2.79e-2 |
| Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 8.92e-3 |
| Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-5 | 2.69e-2 |
| BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 4.01e-3 |
| BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 4.50e-3 |
| BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 1.81e-2 |
| BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 1.33e-2 |
| BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 2.16e-2 |
| BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 1.43e-2 |
| BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 4.61e-2 |
| BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Inactive European Women | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 4.93e-2 |
| BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Inactive European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 2.43e-2 |
| Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 60 And More | MTC | Medina-Gomez | 2018 | NA | 22504 | 5.00e-2 | 1.38e-2 |
| Bone Mineral Density | Lumbar Spine Bone Mineral Density | MTC | Zheng | 2015 | NA | 23699 | 1.00e-2 | 3.97e-2 |
| Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 1.00e-3 | 3.75e-2 |
| Coronary Artery Disease | Coronary Artery Disease Additive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 1.00e-2 | 3.13e-2 |
| Coronary Artery Disease | Coronary Artery Disease Additive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 1.00e-5 | 9.65e-3 |
| Coronary Artery Disease | Myocardial Infarction Additive Model | MTC | Nikpay | 2015 | 27509 | 99121 | 1.00e-3 | 5.71e-3 |
| Coronary Artery Disease | Myocardial Infarction Additive Model | MTC | Nikpay | 2015 | 27509 | 99121 | 1.00e-4 | 8.96e-3 |
| Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Men | MTC | Chu | 2017 | NA | 7050 | 5.00e-2 | 3.77e-2 |
| Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7618 | 1.00e-2 | 2.83e-2 |
| Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7618 | 1.00e-3 | 2.02e-2 |
| Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation All | MTC | Chu | 2017 | NA | 11398 | 5.00e-2 | 1.28e-2 |
| Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Men | MTC | Chu | 2017 | NA | 5699 | 5.00e-2 | 4.41e-2 |
| Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Men | MTC | Chu | 2017 | NA | 5699 | 1.00e-2 | 6.88e-3 |
| Ectopic Fat Traits | Visceral Adipose Tissue Attenutation Men | MTC | Chu | 2017 | NA | 5749 | 1.00e-3 | 3.85e-3 |
| Estimated Glomerular Filtration Rate | Chronic Kidney Disease Without Diabetes | MTC | Pattaro | 2016 | NA | 118448 | 5.00e-2 | 1.09e-2 |
| Estimated Glomerular Filtration Rate | Chronic Kidney Disease Without Diabetes | MTC | Pattaro | 2016 | NA | 118448 | 1.00e-2 | 7.19e-3 |
| Estimated Glomerular Filtration Rate | Cystatin C | MTC | Pattaro | 2016 | NA | 32834 | 5.00e-2 | 2.72e-2 |
| Estimated Glomerular Filtration Rate | Serum Creatinine | MTC | Pattaro | 2016 | NA | 133413 | 5.00e-2 | 1.35e-2 |
| Estimated Glomerular Filtration Rate | Serum Creatinine | MTC | Pattaro | 2016 | NA | 133413 | 1.00e-2 | 4.23e-3 |
| Facial Shape | Mod18 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.79e-3 |
| Facial Shape | Mod18 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.18e-2 |
| Facial Shape | Mod23 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.62e-2 |
| Facial Shape | Mod28 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.28e-2 |
| Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.20e-3 |
| Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.68e-2 |
| Facial Shape | Mod37 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.66e-2 |
| Facial Shape | Mod37 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.38e-2 |
| Facial Shape | Mod4 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 3.87e-2 |
| Facial Shape | Mod43 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 5.58e-3 |
| Facial Shape | Mod52 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.96e-2 |
| Facial Shape | Mod54 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.82e-2 |
| Facial Shape | Mod60 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 5.00e-4 |
| Facial Shape | Mod9 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.43e-2 |
| Forced Expiratory Volume | Forced Expiratory Volume Over Forced Vital Capacity | MTC | Soler-Artigas | 2015 | NA | 38199 | 1.00e-3 | 3.15e-2 |
| Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 5.00e-2 | 1.04e-2 |
| Insulin Secretion | Acute Insulin Response | MTC | Wood | 2017 | NA | 2087 | 5.00e-2 | 9.45e-3 |
| Insulin Secretion | Peak Insulin Response | MTC | Wood | 2017 | NA | 2159 | 1.00e-2 | 2.93e-2 |
| Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 4.64e-2 |
| Ischaemic Stroke | Cardioembolic Stroke | MTC | Traylor | 2012 | 1715 | 12285 | 5.00e-2 | 3.99e-2 |
| Ischaemic Stroke | Cardioembolic Stroke | MTC | Traylor | 2012 | 1715 | 12285 | 1.00e-2 | 1.62e-2 |
| Kidney Function | Serum Creatinine | MTC | Kottgen | 2010 | NA | 67093 | 5.00e-2 | 5.53e-3 |
| Kidney Function | Serum Cystatin | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-2 | 1.37e-2 |
| Lipoprotein Concentrations | Low Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 5.00e-2 | 4.16e-2 |
| Lipoprotein Concentrations | Triglycerides | MTC | Kathiresan | 2009 | NA | 19840 | 5.00e-2 | 2.09e-2 |
| Personality Big5 | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 3.96e-2 |
| Stroke (ischemic) | Cardioembolic Stroke | MTC | Traylor | 2017 | 2365 | 62004 | 5.00e-2 | 4.77e-2 |
| Stroke (ischemic) | Cardioembolic Stroke | MTC | Traylor | 2017 | 2365 | 62004 | 1.00e-2 | 1.94e-3 |
| Smoking | Ever Vs Never Smoked Discrete | MTC | Furberg | 2010 | 39022 | 30387 | 5.00e-2 | 4.32e-2 |
| Statin Efficacy | Delta LDL | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 1.79e-2 |
| Statin Efficacy | Delta LDL | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 1.37e-2 |
| Type 2 Diabetes | Type 2 Diabetes | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-3 | 1.01e-2 |
| SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 5.00e-2 | 3.28e-3 |
| RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-2 | 3.81e-2 |
| RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-3 | 5.33e-3 |
| Facial attractiveness | Facial attractiveness, female raters | ETC | Hu | 2019 | NA | 3928 | 5.00e-2 | 4.78e-2 |
| Facial attractiveness | Facial attractiveness of males, female raters | ETC | Hu | 2019 | NA | 1792 | 5.00e-2 | 4.22e-4 |
| Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-2 | 2.71e-2 |
| Neuroticism | Worry-vulnerability-special-factor-of-neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-3 | 4.88e-2 |
| Neuroticism | Anxiety-tension-special-factor-of-neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-3 | 4.88e-2 |
| Body fat distribution | Body fat distribution-arm-fat-ratio-female | ETC | Andersen | 2019 | NA | 116138 | 1.00e-2 | 1.67e-2 |
| Body fat distribution | Body fat distribution-arm-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 5.00e-3 |
| Body fat distribution | Body fat distribution-arm-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-2 | 1.04e-2 |
| Body fat distribution | Body fat distribution-arm-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-3 | 4.79e-2 |
| Alcohol consumption | Alcohol consumption, drinks-per-week | ETC | Liua | 2019 | NA | 941280 | 5.00e-2 | 3.71e-2 |
| Alcohol consumption | Alcohol consumption, drinks-per-week | ETC | Liua | 2019 | NA | 941280 | 1.00e-2 | 8.15e-3 |
| Alcohol consumption | Alcohol consumption, drinks-per-week | ETC | Liua | 2019 | NA | 941280 | 1.00e-3 | 5.30e-3 |
| Alcohol consumption | Alcohol consumption, drinks-per-week | ETC | Liua | 2019 | NA | 941280 | 1.00e-4 | 1.45e-2 |
| Alcohol consumption | Alcohol consumption, drinks-per-week | ETC | Liua | 2019 | NA | 941280 | 1.00e-5 | 1.48e-2 |
| Nonischemic cardiomyopathy | Nonischemic cardiomyopathy | ETC | Aragam | 2018 | 1816 | 388326 | 5.00e-2 | 2.53e-4 |
| Nonischemic cardiomyopathy | Nonischemic cardiomyopathy | ETC | Aragam | 2018 | 1816 | 388326 | 1.00e-2 | 8.55e-6 |
| Nonischemic cardiomyopathy | Nonischemic cardiomyopathy | ETC | Aragam | 2018 | 1816 | 388326 | 1.00e-3 | 1.93e-2 |
| Heart failure | Heart failure | ETC | Aragam | 2018 | 6504 | 387652 | 5.00e-2 | 3.65e-2 |
| Hippocampal volume | Hippocampal subfield CA1 volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.36e-2 |
| Hippocampal volume | Hippocampal subfield CA1 volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 2.89e-2 |
| IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 5.00e-2 | 2.02e-2 |
| AUD | Alcohol-Use-Disorder | ETC | Kranzler | 2019 | 34658 | 167346 | 1.00e-5 | 2.97e-2 |
| AUDIT-C | Alcohol-Use-Disorder-Identification-Test-Consumption | ETC | Kranzler | 2019 | NA | 200680 | 5.00e-2 | 1.02e-2 |
| AUDIT-C | Alcohol-Use-Disorder-Identification-Test-Consumption | ETC | Kranzler | 2019 | NA | 200680 | 1.00e-2 | 6.55e-3 |
| Medication use | Medication use (beta blocking agents) | ETC | Wu Y | 2019 | 31,700 | 192,324 | 1.00e-2 | 4.28e-2 |
| Medication use | Medication use (diuretics) | ETC | Wu Y | 2019 | 34,453 | 194,633 | 5.00e-2 | 2.51e-2 |
| Medication use | Medication use (calcium channel blockers) | ETC | Wu Y | 2019 | 31,904 | 172,474 | 5.00e-2 | 3.36e-2 |
| Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 5.00e-2 | 2.65e-2 |
| Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-2 | 4.08e-2 |
| Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-4 | 1.95e-2 |
| Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 5.00e-2 | 4.07e-2 |
| Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 1.00e-3 | 3.10e-2 |
| Glomerular filtration rate | Estimated glomerular filtration rate | ETC | Wuttke M | 2019 | NA | 567,460 | 1.00e-3 | 1.18e-2 |
| Glomerular filtration rate | Estimated glomerular filtration rate | ETC | Wuttke M | 2019 | NA | 567,460 | 1.00e-4 | 4.71e-2 |
| Glomerular filtration rate | Estimated glomerular filtration rate | ETC | Wuttke M | 2019 | NA | 567,460 | 1.00e-5 | 2.51e-2 |
| Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 5.00e-2 | 4.43e-2 |
| Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 1.00e-2 | 1.01e-2 |
| same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 1.00e-3 | 4.08e-2 |
| same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 5.00e-2 | 4.39e-2 |
| Alcohol consumption | Alcohol consumption | ETC | Evangelou E | 2019 | NA | 480,842 | 1.00e-2 | 9.21e-3 |
| Alcohol consumption | Alcohol consumption | ETC | Evangelou E | 2019 | NA | 480,842 | 1.00e-3 | 1.57e-2 |
| Alcohol consumption | Alcohol consumption | ETC | Evangelou E | 2019 | NA | 480,842 | 1.00e-4 | 1.33e-2 |
| Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-3 | 2.16e-2 |
| Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-4 | 2.71e-2 |
| Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-5 | 2.99e-2 |
| Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-4 | 4.73e-2 |
| Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 381,152 | 1.00e-2 | 1.46e-2 |
| Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-4 | 1.15e-2 |
| Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-5 | 2.76e-3 |
| Waist to hip ratio | Waist-hip ratio variance | ETC | Wang H | 2019 | NA | 347,134 | 5.00e-2 | 4.47e-2 |
| Uterine fibroids | Uterine fibroids | ETC | Gallagher CS | 2019 | 20,406 | 223,918 | 1.00e-4 | 4.93e-2 |
| Cytokine network | Cytokine network levels (multivariate analysis) | ETC | Nath AP | 2019 | NA | 9,263 | 1.00e-2 | 1.90e-2 |
| Cytokine network | Cytokine network levels (multivariate analysis) | ETC | Nath AP | 2019 | NA | 9,263 | 1.00e-3 | 3.22e-2 |
| BMI by age | BMI at 5 years old | ETC | Helgeland O | 2019 | NA | 4,245 | 5.00e-2 | 4.77e-2 |
| BMI by age | BMI at 5 years old | ETC | Helgeland O | 2019 | NA | 4,245 | 1.00e-2 | 9.99e-3 |
| BMI by age | BMI at 7 years old | ETC | Helgeland O | 2019 | NA | 4,629 | 5.00e-2 | 4.93e-2 |
| Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-2 | 4.66e-3 |
| IL 17 | interleukin 17 receptor B levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 4.77e-2 |
| Metabolic syndrome | Metabolic syndrome | ETC | Lind L | 2019 | NA | 291,107 | 1.00e-5 | 4.72e-2 |
| Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 1.00e-3 | 2.79e-2 |
| Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 1.00e-4 | 3.72e-2 |
| Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 1.00e-5 | 4.40e-2 |
| Snoring | Snoring male | ETC | Campos AI | 2020 | 90,806 | 99,165 | 1.00e-2 | 1.68e-2 |
| Snoring | Snoring male | ETC | Campos AI | 2020 | 90,806 | 99,165 | 1.00e-3 | 3.71e-2 |
| Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 1.00e-4 | 2.89e-2 |
| Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 1.00e-5 | 1.04e-2 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.